HLA Genes as Modifiers of Response to IFN-β-1a Therapy in Relapsing-Remitting Multiple Sclerosis

Abstract

The possibility of genetic screening particularly HLA typing prior to starting IFN-β therapy for MS may permit the identification of likely responders or nonresponders.